
News
Home>News & Events>Presentations>CPP>Critical Path for Parkinson’s: Regulatory Path to Enable Targeting the Right Patients in Clinical Trials of Early Stages of Parkinson’s Disease
109
Related Posts
-
Dr. Stephenson’s presentation at University of Texas Health, San Antonio, The Perry and Ruby Stevens Parkinson’s Disease Center of Excellence: “Critical Path for Parkinson’s Collaboration to Enable Patient Focused Drug Development and Precision Medicine”
-
Using Data to Reimagine Clinical Trials
-
The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson’s and Huntington’s Diseases
-
The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
-
Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease